Cognitive Function and Hormone Therapy in Advanced Prostate Cancer - Interview with Alicia Morgans

November 13, 2017

(Length of Conversation: 7 min)

Dr. Charles Ryan sits down with Dr. Alicia Morgans to discuss the study she's currently leading on Cognitive Effects of Androgen Receptor (AR) Directed Therapies for Advanced Prostate Cancer. This clinical trial studies cognitive function in men with prostate cancer treated with androgen receptor directed therapies such as abiraterone acetate and enzalutamide. Specifically, enzalutamide seems to impact the cognitive vigor of some patients, however Dr. Morgans notes that there is a spectrum of cognitive change that can range from mild impairment to dementia. Currently, there is no real standardized process to identify cognitive function levels, so this is a work in progress that continues to evolve. The goal is to identify those people who are at highest risk and recommend interventions.